• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

    2/14/24 8:42:52 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHVS alert in real time by email
    SC 13G/A 1 tm246235d16_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Pharvaris N.V.

    (Name of Issuer)

     

    Ordinary shares, par value €0.12 per share

    (Title of Class of Securities)

     

    N69605108

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
       
    x Rule 13d-1(c)
       
    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. N69605108Page  2 of 14

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)      (b) ¨

    3. SEC Use Only
       
    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,395,606 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,395,606 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,395,606 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
       
    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.5% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 564,312 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 56,444 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,774,850 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 52,108,675 ordinary shares outstanding as of December 8, 2023 as disclosed in the Issuer’s prospectus supplement dated December 6, 2023 filed with the Securities and Exchange Commission on December 7, 2023.

     

     

    CUSIP No. N69605108Page  3 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Co-Investment Holdings III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)      (b) ¨

    3. SEC Use Only
       
    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,395,606 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,395,606 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,395,606 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
       
    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.5% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 564,312 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 56,444 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,774,850 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 52,108,675 ordinary shares outstanding as of December 8, 2023 as disclosed in the Issuer’s prospectus supplement dated December 6, 2023 filed with the Securities and Exchange Commission on December 7, 2023.

     

     

    CUSIP No. N69605108Page  4 of 14

     

    1.

    Names of Reporting Persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)      (b) ¨

    3. SEC Use Only
       
    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,395,606 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,395,606 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,395,606 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
       
    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.5% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 564,312 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 56,444 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,774,850 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 52,108,675 ordinary shares outstanding as of December 8, 2023 as disclosed in the Issuer’s prospectus supplement dated December 6, 2023 filed with the Securities and Exchange Commission on December 7, 2023.

     

     

    CUSIP No. N69605108Page  5 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Management III, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)      (b) ¨

    3. SEC Use Only
       
    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,395,606 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,395,606 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,395,606 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
       
    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.5% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 564,312 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 56,444 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,774,850 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 52,108,675 ordinary shares outstanding as of December 8, 2023 as disclosed in the Issuer’s prospectus supplement dated December 6, 2023 filed with the Securities and Exchange Commission on December 7, 2023.

     

     

    CUSIP No. N69605108Page  6 of 14

     

    1.

    Names of Reporting Persons

     

    VHCP Management EG, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)      (b) ¨

    3. SEC Use Only
       
    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,395,606 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,395,606 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,395,606 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
       
    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.5% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 564,312 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 56,444 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,774,850 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 52,108,675 ordinary shares outstanding as of December 8, 2023 as disclosed in the Issuer’s prospectus supplement dated December 6, 2023 filed with the Securities and Exchange Commission on December 7, 2023.

     

     

    CUSIP No. N69605108Page  7 of 14

     

    1.

    Names of Reporting Persons

     

    Shah, Nimish

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)      (b) ¨

    3. SEC Use Only
       
    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,395,606 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,395,606 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,395,606 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
       
    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.5% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 564,312 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 56,444 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,774,850 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 52,108,675 ordinary shares outstanding as of December 8, 2023 as disclosed in the Issuer’s prospectus supplement dated December 6, 2023 filed with the Securities and Exchange Commission on December 7, 2023.

     

     

    CUSIP No. N69605108Page  8 of 14

     

    1.

    Names of Reporting Persons

     

    Koh, Bong

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) x (1)      (b) ¨

    3. SEC Use Only
       
    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,395,606 (2)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,395,606 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,395,606 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
       
    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.5% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

           

     

    (1)Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    (2)Consists of (i) 564,312 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 56,444 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,774,850 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    (3)This percentage is calculated based upon 52,108,675 ordinary shares outstanding as of December 8, 2023 as disclosed in the Issuer’s prospectus supplement dated December 6, 2023 filed with the Securities and Exchange Commission on December 7, 2023.

     

     

    CUSIP No. N69605108Page  9 of 14

     

    Introductory Note: This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP III LP, VHCP Co-Investment III, VHCP EG and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of the Ordinary Shares of Pharvaris N.V.

     

    Item 1.
     
      (a)

    Name of Issuer

     

    Pharvaris N.V.

     
      (b)

    Address of Issuer’s Principal Executive Offices

     

    Emmy Noetherweg 2

    2333 BK Leiden

    The Netherlands

     
    Item 2.
     
      (a)

    Name of Person Filing

     

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     
      (b)

    Address of Principal Business Office or, if none, Residence

         
        New York Office: Palo Alto Office:
         
        7 Bryant Park 3340 Hillview Avenue
        23rd Floor Palo Alto, CA 94304
        New York, NY 10018  
     
      (c)

    Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     
      (d)

    Title of Class of Securities

     

    Ordinary shares, par value €0.12 per share

     
      (e)

    CUSIP Number

     

    N69605108

     

     

    CUSIP No. N69605108Page  10 of 14

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable

     

    Item 4. Ownership
       
      (a) Amount beneficially owned as of December 31, 2023:

     

    Venrock Healthcare Capital Partners III, L.P.   3,395,606 (1) 
    VHCP Co-Investment Holdings III, LLC   3,395,606 (1) 
    Venrock Healthcare Capital Partners EG, L.P.   3,395,606 (1) 
    VHCP Management III, LLC   3,395,606 (1) 
    VHCP Management EG, LLC   3,395,606 (1) 
    Nimish Shah   3,395,606 (1) 
    Bong Koh   3,395,606 (1) 

     

      (b) Percent of class as of December 31, 2023:

     

    Venrock Healthcare Capital Partners III, L.P.    6.5% (2) 
    VHCP Co-Investment Holdings III, LLC    6.5% (2) 
    Venrock Healthcare Capital Partners EG, L.P.    6.5% (2) 
    VHCP Management III, LLC    6.5% (2) 
    VHCP Management EG, LLC    6.5% (2) 
    Nimish Shah    6.5% (2) 
    Bong Koh    6.5% (2) 

     

      (c) Number of shares as to which the person has, as of December 31, 2023:
         
        (i) Sole power to vote or to direct the vote:

     

    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

        (ii) Shared power to vote or to direct the vote:

     

    Venrock Healthcare Capital Partners III, L.P.   3,395,606 (1) 
    VHCP Co-Investment Holdings III, LLC   3,395,606 (1) 
    Venrock Healthcare Capital Partners EG, L.P.   3,395,606 (1) 
    VHCP Management III, LLC   3,395,606 (1) 
    VHCP Management EG, LLC   3,395,606 (1) 
    Nimish Shah   3,395,606 (1) 
    Bong Koh   3,395,606 (1) 

     

     

    CUSIP No. N69605108Page  11 of 14

     

        (iii) Sole power to dispose or to direct the disposition of:

     

    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

        (iv) Shared power to dispose or to direct the disposition of:

     

    Venrock Healthcare Capital Partners III, L.P.   3,395,606 (1) 
    VHCP Co-Investment Holdings III, LLC   3,395,606 (1) 
    Venrock Healthcare Capital Partners EG, L.P.   3,395,606 (1) 
    VHCP Management III, LLC   3,395,606 (1) 
    VHCP Management EG, LLC   3,395,606 (1) 
    Nimish Shah   3,395,606 (1) 
    Bong Koh   3,395,606 (1) 

     

    (1)Consists of (i) 564,312 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 56,444 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,774,850 shares held by Venrock Healthcare Capital Partners EG, L.P. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.

     

    (2)This percentage is calculated based upon 52,108,675 ordinary shares outstanding as of December 8, 2023 as disclosed in the Issuer’s prospectus supplement dated December 6, 2023 filed with the Securities and Exchange Commission on December 7, 2023.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨

     

     

    CUSIP No. N69605108Page  12 of 14

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable
     
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
       
    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

    CUSIP No. N69605108Page  13 of 14

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

    Venrock Healthcare Capital Partners III, L.P.   Venrock Healthcare Capital Partners EG, L.P.
             
    By: VHCP Management III, LLC   By: VHCP Management EG, LLC
    Its: General Partner   Its: General Partner
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
             
    VHCP Co-Investment Holdings III, LLC      
             
    By: VHCP Management III, LLC      
    Its: Manager      
             
    By: /s/ Sherman G. Souther      
      Name: Sherman G. Souther      
      Its: Authorized Signatory      
             
    VHCP Management III, LLC   VHCP Management EG, LLC
             
    By: /s/ Sherman G. Souther   By: /s/ Sherman G. Souther
      Name: Sherman G. Souther     Name: Sherman G. Souther
      Its: Authorized Signatory     Its: Authorized Signatory
             
    Nimish Shah      
           
    /s/ Sherman G. Souther      
    Sherman G. Souther, Attorney-in-fact      
             
    Bong Koh      
           
    /s/ Sherman G. Souther      
    Sherman G. Souther, Attorney-in-fact      

     

     

    CUSIP No. N69605108Page  14 of 14

     

    EXHIBITS

     

    A:Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on November 30, 2023)

     

    B:Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed November 30, 2023)

     

    C:Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on November 30, 2023)

     

     

     

    Get the next $PHVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHVS

    DatePrice TargetRatingAnalyst
    4/29/2025$28.00Overweight
    Cantor Fitzgerald
    9/25/2023$27.00Outperform
    Wedbush
    8/15/2023$10.00 → $34.00Equal-Weight → Overweight
    Morgan Stanley
    10/5/2022$16.00Buy
    Bryan Garnier
    9/13/2022$34.00 → $18.00Mkt Outperform
    JMP Securities
    8/23/2022$40.00 → $10.00Overweight → Equal-Weight
    Morgan Stanley
    8/22/2022$26.00 → $13.00Neutral → Underperform
    BofA Securities
    5/25/2022$34.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $PHVS
    SEC Filings

    See more
    • SEC Form 6-K filed by Pharvaris N.V.

      6-K - Pharvaris N.V. (0001830487) (Filer)

      4/7/25 6:51:03 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by Pharvaris N.V.

      20-F - Pharvaris N.V. (0001830487) (Filer)

      4/7/25 6:50:27 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Pharvaris N.V.

      6-K - Pharvaris N.V. (0001830487) (Filer)

      1/13/25 6:51:02 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesEnrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026Orphan medicinal product designation granted to deucrictibant in Europe for the treatment of bradykinin-mediated angioedemaData presented at recent congresses reinforces the value of deucrictibant by highlighting its ability to maintain a reduced attack rate in long-term prophylaxis, and potential to rapidly and completely treat HAE attacks, including in participants experiencing upper-ai

      4/7/25 6:58:03 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

      ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that the European Commission (EC) has granted orphan designation to its investigational drug, deucrictibant, for the treatment of bradykinin-mediated angioedema. The U.S. Food and Drug Administration (FDA) previously granted orphan drug designation to deucrictibant for the treatment of bradykinin-mediated angioedema in M

      4/1/25 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

      Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero daysAll participants in CHAPTER-1 OLE who had reached week 62 reported improved health-related quality of lifeOngoing RAPIDe-2 extension study includes efficacy data from seven upper airway, including laryngeal, attacks; median time to onset of symptom relief was 0.9 hours (N=7)In both extension studies, deucrictibant was generally well tolerated with no safety signals observed ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradyki

      3/3/25 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

      SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

      2/14/24 8:42:52 PM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

      SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

      2/14/24 10:27:18 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

      SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

      2/13/24 2:14:59 PM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHVS
    Leadership Updates

    Live Leadership Updates

    See more
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments
    • Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

      ZUG, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of Stefan Abele, Ph.D., as Chief Technical Operations Officer. In this role, he will be responsible for all chemistry, manufacturing, and controls (CMC) activities, supply chain, and program management as Pharvaris progresses into late-stage clinical development. Dr. Abele joins Pharvaris with more than 20 years of experience in process development, end-to-end Active Pharmaceutical Ingredients (API) supply chain, cross-functional CMC activities

      11/15/23 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update

      Formal letters received from FDA relating to the previously announced hold on clinical studies of PHA121 in the U.S.Top-line data anticipated in 4Q22 for RAPIDe-1, a global Phase 2 study of PHVS416 for the acute treatment of HAE attacks ongoing outside the U.S.Executing from a strong financial position with cash and cash equivalents of €201 million as of June 30, 2022 ZUG, Switzerland, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the second quarter ended June 30, 2022, and provided a business update

      9/12/22 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHVS
    Financials

    Live finance-specific insights

    See more
    • Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

      CHAPTER-3, the global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment for HAE using once-daily extended-release tablet, is expected to initiate by YE2024Differentiated deucrictibant profile, including long-term extension results, to be highlighted in clinical, real-world, nonclinical, and discovery data presentations at the 2024 Bradykinin SymposiumPharvaris intends to pursue clinical development in acquired angioedema as a newly named indicationPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 rece

      9/5/24 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

      Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to placebo92.3% reduction in occurrence of moderate and severe attacks92.6% fewer attacks treated with on-demand medication by participantsDeucrictibant well-toleratedPharvaris to host a conference call today at 8:00 a.m. EST ZUG, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the CHAPTER-1 Phase 2 clinical study meeting its primary endpoi

      12/6/23 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

      Primary endpoint met, substantially reducing HAE attack symptomsAll secondary endpoints metPHVS416 was well tolerated at all dose levelsPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the RAPIDe-1 Phase 2 clinical study, demonstrating statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks. Pharvaris plans to present data from the study at future medical meetings. RAPIDe-1 Clinical Stu

      12/8/22 6:50:00 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Pharvaris N.V. with a new price target

      Cantor Fitzgerald initiated coverage of Pharvaris N.V. with a rating of Overweight and set a new price target of $28.00

      4/29/25 8:11:22 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Pharvaris N.V. with a new price target

      Wedbush initiated coverage of Pharvaris N.V. with a rating of Outperform and set a new price target of $27.00

      9/25/23 7:40:10 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pharvaris N.V. upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Pharvaris N.V. from Equal-Weight to Overweight and set a new price target of $34.00 from $10.00 previously

      8/15/23 7:24:38 AM ET
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care